http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
First Data On Direct Costs of Lung Cancer Management in Morocco
Tachfouti, N.,Belkacemi, Y.,Raherison, C.,Bekkali, R.,Benider, A.,Nejjari, C. Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.4
Background: Lung cancer is the leading cause of cancer morbidity and mortality. Its management has a significant economic impact on society. Despite a high incidence of cancer, so far, there is no national register for this disease in Morocco. The main goal of this report was to estimate the medical costs of lung cancer in our country. Methods: We first estimated the number of annual new cases according to stage of the disease on the basis of the Grand-Casablanca-Region Cancer Registry data. For each sub-group, the protocol of treatment was described taking into account the international guidelines, and an evaluation of individual costs during the first year following diagnosis was made. Extrapolation of the results to the whole country was used to calculate the total annual cost of treatments for lung cancer in Morocco. Results: Overall approximately 3,500 new cases of lung cancer occur each year in the country. Stages I and II account for only 4% of cases, while 96% are diagnosed at locally advanced or metastatic stages III and IV. The total medical cost of lung cancer in Morocco is estimated to be around USD 12 million. This cost represents approximately 1% of the global budget of the Health Department. According to AROME Guidelines, about 86% of the newly diagnosed lung cancer cases needed palliative treatment while 14% required curative intent therapy. The total cost of early and advanced stages lung cancer management during the first year were estimated to be 4,600 and 3,420 USD, respectively. Conclusion: This study provides health decision-makers with a first estimate of costs and the opportunity to achieve the optimal use of available data to estimate the needs of health facilities in Morocco. A substantial proportion of the burden of lung cancer could be prevented through the application of existing cancer control knowledge and by implementing tobacco control programs.
Ternary-mixture quantification of ceramic raw materials
K. Moussaceb,D. Merabet,H. Belkacemi,S. Aouiche 한양대학교 세라믹연구소 2011 Journal of Ceramic Processing Research Vol.12 No.4
The mechanical properties of a ceramic are the favored criteria to measure its qualities. For this purpose, we present in this article a new technique which consists in improving the mechanical properties by strengthening the structure of the ceramic with polymers. The amount of incorporated polymer, in a kaolin reference, is used as a criterion for the optimization of the mechanical properties of a hybrid refractory ceramic. The formulation of the mixture, in ceramic, optimized rests on a new methodology of mixture calculation and a mathematical multiple linear regression analysis (MLRA). In conclusion, the optimal mechanical properties were recorded for the optimized formula giving a mixture of 80% of hybrid kaolin, 20% of by-products GW1 and GW2 and 16% of polyethylene glucose (PEG) (PEG1500 and PEG6000). This result was confirmed by various physical tests such as the X-ray Diffraction (XRD) and the mechanical tests.
Laurent Mineur,Frederi Plat,Françoise Desseigne,Gael Deplanque,Mohamed Belkacemi,Laurence Moureau-Zabotto,Carlos D. Beyrne,Khadija Jalali,Stéphane Obled,Denis Smith,Léa Vazquez,Rania Boustany 대한암학회 2024 Cancer Research and Treatment Vol.56 No.2
Purpose Preoperative chemoradiation (CRT) is expected to increase the rate of curative resection and complete histological response. In this trial, we investigated the efficacy of a neoadjuvant CRT regimen in gastric adenocarcinoma (NCT01565109 trial).Materials and Methods Patients with stage IB to IIIC gastric adenocarcinoma, endoscopy ultrasound and computed tomography–scan diagnosed, were eligible for this phase II trial. Neoadjuvant treatment consisted of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil [5FU]) followed by preoperative CRT with oxaliplatin, continuous 5FU and radiotherapy (45 Gy in 25 fractions of 1.8 Gy, 5 fractions per week for 5 weeks) administered before surgery. R0-resection rate, pathological complete response (pathCR) rate, and survival (progression-free survival [PFS] and overall survival [OS]) were evaluated as primary endpoints.Results Among 33 patients included, 32 patients (97%) received CRT and 26 (78.8%) were resected (R0 resection for all patients resected). Among resected patients, we report pathCR in 23,1% and pathologic major response (tumor regression grade 2 according to Mandard’s classification) in 26,9%. With a median follow-up duration of 5.82 years (range, 0.4 to 9.24 years), the estimated median OS for all 33 patients was not reached; 1-, 3-, and 5-year OS rates were 85%, 61%, and 52%, respectively. Among resected patients, those whose histological response was tumor grade regression (TRG) 1-2 had significantly better OS and PFS rates than those with a TRG 3-4-5 response (p=0.019 and p=0.016, respectively).Conclusion Promising results from trials involving preoperative chemoradiation followed by surgery in gastric cancer need to be further evaluated in a phase III trial.